



**Supplementary Figure 1. Adjusted Associations between Plasma TNFR1 and TNFR 2 Levels and Renal Outcomes**



Supplementary Figure 2. Selection of Participants and Renal Endpoints in the VA NEPHRON-D Cohort



**Supplementary Table 1. ORs and 95% CIs for the Renal Endpoint by Quartiles of Plasma Biomarkers in Both Cohorts**

	<b>Model 1 Odds Ratio (95% CI)</b>	<b>Model 2 Odds Ratio (95% CI)</b>	<b>Model 3 Odds Ratio (95% CI)</b>
<b>ACCORD</b>			
<b>TNFR1</b>			
<=1528 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
1529 to 2043 pg/ml	1.36 (0.73-2.57)	1.29 (0.68-2.45)	1.01 (0.46-2.24)
2044 to 2690 pg/ml	3.08 (1.56-6.09)	3.02 (1.50-6.07)	2.29 (1.02-5.17)
>=2691 pg/ml	4.39 (2.16-8.92)	4.20 (1.99-8.87)	2.99 (1.23-7.25)
<b>TNFR2</b>			
<=5163 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
5164-6317 pg/ml	3.33 (1.61-6.87)	3.54 (1.67-7.54)	2.98 (1.21-7.35)
6318-8082 pg/ml	6.06 (2.83-12.95)	6.60 (2.99-14.56)	6.48 (2.59-16.20)
>=8083 pg/ml	8.42 (3.70-18.71)	9.05 (3.79-22.60)	8.37 (3.00-23.41)
<b>KIM-1</b>			
<=109 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
110-158 pg/ml	3.10 (1.64-5.87)	3.04 (1.58-5.83)	2.48 (1.16-5.31)
159-265 pg/ml	3.11 (1.57-6.19)	2.93 (1.45-5.94)	3.07 (1.27-7.48)
>=266 pg/ml	6.17 (2.93-12.99)	5.23 (2.42-11.30)	7.52 (2.83-20.01)
<b>VA NEPHRON-D</b>			
<b>TNFR1</b>			
<=3104 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
3105 to 4186 pg/ml	1.00(0.56-1.79)	0.97(0.53-1.75)	1.07(0.59-1.96)
4187 to 5810 pg/ml	1.46(0.85-2.50)	1.43(0.80-2.57)	1.55(0.86-2.82)
>=5811 pg/ml	3.25(1.99-5.32)	2.99(1.68-5.33)	3.45(1.90-6.27)
<b>TNFR2</b>			
<=8182 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
8183 to 10699 pg/ml	2.13(1.16-3.91)	2.09(1.12-3.88)	2.05(1.09-3.84)
10700 to 13813 pg/ml	2.50(1.38-4.52)	2.39(1.26-4.51)	2.28(1.19-4.34)
>=13814 pg/ml	4.46(2.54-7.84)	3.88(2.06-7.32)	3.80(1.99-7.26)
<b>KIM-1</b>			
<=235 pg/ml	1 (Ref)	1 (Ref)	1 (Ref)
236 to 406 pg/ml	1.58(0.77-3.24)	1.53(0.74-3.15)	1.61(0.78-3.33)

407 to 709 pg/ml	3.51(1.84-6.70)	3.17(1.63-6.15)	3.12(1.60-6.11)
>=710 pg/ml	7.99(4.33-14.75)	6.85(3.56-13.15)	6.33(3.26-12.31)

Model 1: individual biomarker only

Model 2: Model 1 + study design: treatment arm, baseline eGFR, albuminuria

Model 3: Model 2 + age, race, SBP, DBP, medications (Fibrates/ ACE-Inhibitors/Angiotensin Receptor Blockers)

Model 4: Model 3 + all biomarkers

In ACCORD renal endpoint is defined as achieving an estimated eGFR <60 mL/min/1.73m<sup>2</sup> along with a sustained (on two or more visits  $\geq$ 3 months apart) decline in eGFR of  $\geq$  40% from baseline eGFR. In VA NEPHRON-D, renal outcome is defined as the occurrence of a decline in the eGFR (an absolute decrease of  $\geq$ 30 mL/min/1.73m<sup>2</sup> if the estimated GFR was  $\geq$ 60 mL/min/1.73m<sup>2</sup> at randomization or a relative decrease of  $\geq$ 50% if the estimated GFR was <60 mL/min/1.73m<sup>2</sup>) or ESRD (defined by the initiation of maintenance dialysis, receipt of kidney transplant, or an estimated GFR of <15 mL/min/1.73m<sup>2</sup>).